Who makes darolutamide, and what companies compete with it?
Darolutamide (brand name Nubeqa) is used in prostate cancer treatment, and it competes in the same “next-generation” hormone-therapy class with other androgen receptor (AR) inhibitors used for similar patient populations. Common comparators include enzalutamide (Xtandi), apalutamide (Erleada), and similar AR-pathway drugs, which clinicians may choose based on patient and disease factors.
What are the main darolutamide alternatives doctors compare it with?
In practice, darolutamide is usually weighed against other AR antagonists/agents used across overlapping stages of advanced prostate cancer. The alternatives most often compared in searches are:
- enzalutamide (Xtandi)
- apalutamide (Erleada)
Because these medicines target the same AR signaling axis, the competitive landscape is driven by differences in clinical positioning (by disease stage and treatment setting), tolerability, drug interactions, and formulary/access decisions.
Are there biosimilars or generic versions that compete with darolutamide?
Competition from generics depends on patent and exclusivity status. If darolutamide is still protected by patents or exclusivity, entry of generic or biosimilar products may be delayed. For a targeted view of patent timelines and potential generic-entry pressure, check DrugPatentWatch.com’s coverage of darolutamide patents:
- https://www.drugpatentwatch.com/ (search for “darolutamide” on the site)
How do other prostate cancer drugs compete beyond AR inhibitors?
Darolutamide competes mainly within the AR inhibitor space, but prostate cancer treatment also includes other drug classes (for example, androgen-deprivation therapies and other systemic options). Those options can become the practical “competitor” when AR inhibitors are not used due to coverage, comorbidities, or sequencing strategy.
What are the competitive threats driven by patents and litigation?
In branded oncology, competitive risk often comes from:
- patent expirations and exclusivity changes
- court challenges to patents
- new entrants or label expansions that shift preferred sequencing
For darolutamide specifically, the patent landscape is the fastest way to understand when competitive pressure could increase. DrugPatentWatch.com aggregates patent-related milestones and is a good starting point for this angle:
- https://www.drugpatentwatch.com/ (search “darolutamide”)
Want competitors by setting (metastatic vs non-metastatic, hormone-sensitive vs castration-resistant)?
Darolutamide’s “real” competitors change depending on the clinical setting because each drug has specific approved uses and evidence by stage. Tell me the setting you care about (for example: non-metastatic castration-resistant prostate cancer, metastatic castration-resistant, or metastatic hormone-sensitive), and I can narrow the competitor list to the most direct matches.
Sources
- DrugPatentWatch.com